AU2015249232B2 - Method of treating lung adenocarcinoma - Google Patents

Method of treating lung adenocarcinoma Download PDF

Info

Publication number
AU2015249232B2
AU2015249232B2 AU2015249232A AU2015249232A AU2015249232B2 AU 2015249232 B2 AU2015249232 B2 AU 2015249232B2 AU 2015249232 A AU2015249232 A AU 2015249232A AU 2015249232 A AU2015249232 A AU 2015249232A AU 2015249232 B2 AU2015249232 B2 AU 2015249232B2
Authority
AU
Australia
Prior art keywords
ros1
compound
pharmaceutically acceptable
fusion
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015249232A
Other languages
English (en)
Other versions
AU2015249232A1 (en
Inventor
Dana T. Aftab
Peiwen Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53055132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015249232(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2015249232A1 publication Critical patent/AU2015249232A1/en
Application granted granted Critical
Publication of AU2015249232B2 publication Critical patent/AU2015249232B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015249232A 2014-04-25 2015-04-27 Method of treating lung adenocarcinoma Active AU2015249232B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461984599P 2014-04-25 2014-04-25
US61/984,599 2014-04-25
PCT/US2015/027800 WO2015164869A1 (en) 2014-04-25 2015-04-27 Method of treating lung adenocarcinoma

Publications (2)

Publication Number Publication Date
AU2015249232A1 AU2015249232A1 (en) 2016-11-10
AU2015249232B2 true AU2015249232B2 (en) 2020-06-25

Family

ID=53055132

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015249232A Active AU2015249232B2 (en) 2014-04-25 2015-04-27 Method of treating lung adenocarcinoma

Country Status (21)

Country Link
US (1) US20170042880A1 (enExample)
EP (2) EP3906921A1 (enExample)
JP (2) JP6696908B2 (enExample)
KR (1) KR102474701B1 (enExample)
CN (1) CN106488768A (enExample)
AR (1) AR100191A1 (enExample)
AU (1) AU2015249232B2 (enExample)
BR (1) BR112016024672A2 (enExample)
CA (1) CA2946416C (enExample)
DK (1) DK3134084T3 (enExample)
EA (1) EA035223B1 (enExample)
ES (1) ES2874875T3 (enExample)
HU (1) HUE054557T2 (enExample)
IL (1) IL248408B (enExample)
MX (1) MX375716B (enExample)
PL (1) PL3134084T3 (enExample)
PT (1) PT3134084T (enExample)
SG (1) SG11201608657QA (enExample)
TW (1) TWI724988B (enExample)
UA (1) UA121655C2 (enExample)
WO (1) WO2015164869A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2704717A1 (en) 2011-05-02 2014-03-12 Exelixis, Inc. Method of treating cancer and bone cancer pain
CN106255499A (zh) 2014-03-17 2016-12-21 埃克塞里艾克西斯公司 卡博替尼制剂的给药
EA033834B1 (ru) 2014-07-31 2019-11-29 Exelixis Inc Способ получения кабозантиниба, меченного фтором-18, и его аналогов
MA40457A (fr) 2014-08-05 2017-06-14 Exelixis Inc Combinaison de médicaments pour traiter le myélome multiple
US11141413B2 (en) 2016-04-15 2021-10-12 Exelixis, Inc. Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
CN107353246A (zh) * 2016-12-27 2017-11-17 辅仁药业集团熙德隆肿瘤药品有限公司 一种制备抗肿瘤药物卡博替尼的方法
EP3631011B1 (en) * 2017-05-31 2021-06-23 Roche Diagnostics GmbH Multiplex pcr detection of alk, ret, and ros fusions
US11504362B2 (en) 2017-06-09 2022-11-22 Exelixis, Inc. Liquid dosage forms to treat cancer
CN107541550A (zh) * 2017-08-21 2018-01-05 上海派森诺生物科技股份有限公司 人ros1融合基因检测方法
EP3685166A2 (en) * 2017-09-20 2020-07-29 Mersana Therapeutics, Inc. Compositions and methods for predicting response to napi2b-targeted therapy
SG11202006945PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
AU2019212800B2 (en) * 2018-01-26 2024-05-23 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
HRP20251184T1 (hr) 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
AR119069A1 (es) * 2019-06-04 2021-11-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de quinasas
DE102020005002A1 (de) * 2020-08-17 2022-02-17 Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh Mittel zur Therapie von Tumorerkrankungen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039971A1 (en) * 2012-09-07 2014-03-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5756696A (en) 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US20100143918A1 (en) 2007-01-19 2010-06-10 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
EP3072963B1 (en) 2007-10-18 2020-04-01 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
TW201920110A (zh) * 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
SI2881402T1 (sl) 2009-02-12 2017-12-29 Cell Signaling Technology, Inc. Ekspresija mutantnega ros pri humanem raku jeter
TWI585088B (zh) * 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039971A1 (en) * 2012-09-07 2014-03-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. DRILON ET AL, "Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas", CANCER DISCOVERY, (2013-03-26), vol. 3, no. 6, doi:10.1158/2159-8290.CD-13-0035, ISSN 2159-8274, pages 630 - 635 *
TAKASHI KOHNO ET AL, "RET fusion gene: Translation to personalized lung cancer therapy", CANCER SCIENCE, (2013-11-01), vol. 104, no. 11, doi:10.1111/cas.12275, ISSN 1347-9032, pages 1396 - 1400 *

Also Published As

Publication number Publication date
AR100191A1 (es) 2016-09-14
PL3134084T3 (pl) 2021-09-27
MX375716B (es) 2025-03-06
IL248408A0 (en) 2016-11-30
SG11201608657QA (en) 2016-11-29
EP3906921A1 (en) 2021-11-10
MX2016013600A (es) 2017-04-27
EP3134084B1 (en) 2021-03-17
HUE054557T2 (hu) 2021-09-28
CN106488768A (zh) 2017-03-08
WO2015164869A1 (en) 2015-10-29
JP2019189646A (ja) 2019-10-31
ES2874875T3 (es) 2021-11-05
PT3134084T (pt) 2021-05-11
KR102474701B1 (ko) 2022-12-05
EP3134084A1 (en) 2017-03-01
TWI724988B (zh) 2021-04-21
EA035223B1 (ru) 2020-05-18
JP2017513908A (ja) 2017-06-01
DK3134084T3 (da) 2021-05-03
UA121655C2 (uk) 2020-07-10
IL248408B (en) 2022-06-01
NZ725576A (en) 2021-03-26
CA2946416A1 (en) 2015-10-29
JP6696908B2 (ja) 2020-05-20
BR112016024672A2 (pt) 2021-02-02
CA2946416C (en) 2022-07-19
US20170042880A1 (en) 2017-02-16
TW201622723A (zh) 2016-07-01
EA201692150A1 (ru) 2017-02-28
AU2015249232A1 (en) 2016-11-10
KR20160147934A (ko) 2016-12-23

Similar Documents

Publication Publication Date Title
EP3134084B1 (en) Method of treating lung adenocarcinoma
EP2892532B1 (en) Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
WO2022087270A1 (en) Methods for treatment of lung cancers
EP3030577B1 (en) Novel nrg1 fusion genes in cancer
HK40064013A (en) Method of treating lung adenocarcinoma
JP7747459B2 (ja) Ｆｇｆｒ阻害薬に対する感受性の判定方法
US20200010904A1 (en) Method of predicting effects of cdc7 inhibitor
HK1235005B (en) Method of treating lung adenocarcinoma
WO2022192232A1 (en) Ep300 degrader and uses thereof in neuroblastoma
NZ725576B2 (en) Method of treating lung adenocarcinoma
JP5119546B2 (ja) 胃を原発巣とする消化管間質腫瘍の悪性化の診断法
HK40071406A (en) Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
HK1212248B (en) Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
CN110234773A (zh) 治疗含融合基因的癌症的方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)